MET amplification has emerged as a known mechanism of resistance in a subset of patients (approximately 7–15%) with non-small cell lung cancer (NSCLC) harboring EGFR mutations and receiving treatment with EGFR tyrosine kinase inhibitors (TKIs) when experiencing disease progression [117]. This evidence concerns the gene MET and non-small cell lung carcinoma.